Investors Buy Large Volume of Put Options on Centessa Pharmaceuticals (NASDAQ:CNTA)

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) was the recipient of unusually large options trading activity on Wednesday. Stock investors purchased 10,659 put options on the company. This represents an increase of approximately 1,668% compared to the typical daily volume of 603 put options.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CNTA. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Finally, Oppenheimer increased their price target on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 120,029 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.25, for a total value of $3,150,761.25. Following the sale, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. This represents a 65.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the sale, the insider owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 349,073 shares of company stock worth $9,429,412. Company insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $80,000. T. Rowe Price Investment Management Inc. grew its position in Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after purchasing an additional 1,516 shares during the period. Coastal Bridge Advisors LLC increased its stake in Centessa Pharmaceuticals by 7.1% during the 4th quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock valued at $351,000 after purchasing an additional 931 shares in the last quarter. XTX Topco Ltd bought a new stake in Centessa Pharmaceuticals during the 4th quarter valued at $1,978,000. Finally, Voloridge Investment Management LLC acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth $8,710,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals News Summary

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Lilly agrees to acquire Centessa for up to $7.8 billion — $38 in cash per share plus a contingent value right (CVR) for additional milestones, bringing Centessa’s pipeline (notably OX2R agonists for sleep/wake disorders) into Lilly’s neuroscience franchise. This is the primary catalyst lifting CNTA shares. Eli Lilly to acquire Centessa in $6.3B deal
• Neutral Sentiment: Unusual options flow — recent spikes in both calls and puts (large put block of 10,659 contracts reported) signal significant hedging/speculation and likely higher intraday volatility as arbitrageurs and speculators position around the deal and CVR outcome.
• Negative Sentiment: Shareholder law firms have launched investigations and issued alerts questioning whether the $38 cash + CVR structure reflects a fair process and price for public shareholders, raising the prospect of litigation or delay. Investor Alert — Kahn Swick & Foti
• Negative Sentiment: Multiple analyst downgrades (Needham, Wolfe Research, Stephens moved ratings toward Hold) reduce near‑term buy-side support and reflect concerns over deal dynamics/valuation and near-term upside beyond the offer. Needham downgrade
• Negative Sentiment: Recent quarter missed EPS expectations (reported $(0.48) vs. consensus $(0.38)), underscoring execution/financial risks if the deal faces delay or renegotiation. Earnings release / MarketBeat

Centessa Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ CNTA traded down $0.03 during trading on Wednesday, hitting $39.70. 8,399,772 shares of the company traded hands, compared to its average volume of 2,286,323. The firm has a market capitalization of $5.80 billion, a price-to-earnings ratio of -21.69 and a beta of 1.55. The business’s fifty day moving average is $26.29 and its 200 day moving average is $25.24. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. Centessa Pharmaceuticals has a fifty-two week low of $9.60 and a fifty-two week high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, March 31st. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.10). Equities research analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.